KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Income from Continuing Operations: 2018-2024

Historic Income from Continuing Operations for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $18.2 million.

  • Castle Biosciences' Income from Continuing Operations fell 122.08% to -$501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 300.86%. This contributed to the annual value of $18.2 million for FY2024, which is 131.75% up from last year.
  • As of FY2024, Castle Biosciences' Income from Continuing Operations stood at $18.2 million, which was up 131.75% from -$57.5 million recorded in FY2023.
  • Castle Biosciences' Income from Continuing Operations' 5-year high stood at $18.2 million during FY2024, with a 5-year trough of -$67.1 million in FY2022.
  • For the 3-year period, Castle Biosciences' Income from Continuing Operations averaged around -$35.5 million, with its median value being -$57.5 million (2023).
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 294.88% in 2020, then surged by 131.75% in 2024.
  • Yearly analysis of 5 years shows Castle Biosciences' Income from Continuing Operations stood at -$10.3 million in 2020, then slumped by 204.28% to -$31.3 million in 2021, then tumbled by 114.55% to -$67.1 million in 2022, then grew by 14.41% to -$57.5 million in 2023, then skyrocketed by 131.75% to $18.2 million in 2024.